Amalia Lisda
Department of Neurology, Medical Faculty, Universitas Padjadjaran, Bandung, Indonesia.
J Blood Med. 2023 Oct 11;14:537-542. doi: 10.2147/JBM.S429357. eCollection 2023.
Hypercoagulable state in acute ischemic stroke patients with COVID-19, was found to occur in most cases, may affect the severity and clinical outcome of acute ischemic stroke with COVID-19. Ischemic stroke patients with COVID-19 infection have worsen prognosis in mortality regarding hypercoagulable state condition.
The study aims to determine the relationship between the hypercoagulable state and the severity of acute ischemic stroke patients with COVID-19.
This study is a retrospective analytic study using a cross-sectional method in acute ischemic stroke who meet the criteria must have focal clinical symptoms or global dysfunction lasting more than 24 hours, be caused by vascular factors, be confirmed positive for COVID-19, NIHSS (admission and discharge), and have an examination of D-dimer and/or fibrinogen. Chi-Square is used for data processing relationship analysis.
A total of 32 patients met the inclusion and exclusion criteria of this study. Elevated D-dimer and/or fibrinogen were found in 28 patients (87.5%), confirming a hypercoagulable state. In this study, the average value of D-dimer was 5.3 mg/mL, and fibrinogen was 479 mg/dL. Based on the admission NIHSS score, it was found that most of the patients had moderate strokes with an average NIHSS score of 12. The chi-square test results showed no relationship between the hypercoagulable state and the severity of acute ischemic stroke as measured by NIHSS admission (p=0.333), but it was closely related to NIHSS exit (p=0.02). The finding supports that 40.62% of acute ischemic stroke patients with COVID-19 confirmed to have a hypercoagulable state had a death discharge status.
There is no significant relationship between hypercoagulable state and stroke severity on admission, but it closely related to NIHSS on discharge and high mortality in acute ischemic stroke patients with COVID-19.
在大多数新型冠状病毒肺炎(COVID-19)合并急性缺血性脑卒中患者中发现存在高凝状态,这可能会影响COVID-19合并急性缺血性脑卒中的严重程度及临床结局。COVID-19感染的缺血性脑卒中患者在高凝状态下死亡率的预后更差。
本研究旨在确定COVID-19合并急性缺血性脑卒中患者的高凝状态与疾病严重程度之间的关系。
本研究为回顾性分析研究,采用横断面研究方法,纳入符合标准的急性缺血性脑卒中患者,这些患者必须有持续超过24小时的局灶性临床症状或整体功能障碍,由血管因素引起,COVID-19核酸检测呈阳性,有美国国立卫生研究院卒中量表(NIHSS,入院及出院时)评分,且进行了D-二聚体和/或纤维蛋白原检测。采用卡方检验进行数据处理及关系分析。
共有32例患者符合本研究的纳入及排除标准。28例患者(87.5%)检测发现D-二聚体和/或纤维蛋白原升高,证实存在高凝状态。本研究中,D-二聚体的平均值为5.3mg/mL,纤维蛋白原为479mg/dL。根据入院时NIHSS评分,发现大多数患者为中度卒中,平均NIHSS评分为12分。卡方检验结果显示,以入院时NIHSS评分衡量,高凝状态与急性缺血性脑卒中的严重程度之间无相关性(p=0.333),但与出院时NIHSS评分密切相关(p=0.02)。该研究结果支持40.62%确诊为高凝状态的COVID-19合并急性缺血性脑卒中患者出院时死亡。
高凝状态与COVID-19合并急性缺血性脑卒中患者入院时的卒中严重程度无显著相关性,但与出院时NIHSS评分密切相关,且死亡率较高。